Pancreatic Cancer Research

ResearcherKyushu UniversityNo recent work listed

Yoshihiko Maehara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1532-3537; OpenAlex author ID A5004420462. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 3 papers · 2015: 4 papers · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 2 papers

Papers 15

  1. Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer. Last author DOI 10.1007/s00535-018-01535-9↗
  2. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer. Last author DOI 10.1016/j.jss.2019.02.038↗
  3. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Last author DOI 10.1002/cam4.1087↗
  4. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.3892/ijo.2016.3804↗
  5. Surgical Results of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: a Multi-institutional Retrospective Study of 174 patients. Last author PMID 27127150↗
  6. Cofilin-phosphatase slingshot-1L (SSH1L) is over-expressed in pancreatic cancer (PC) and contributes to tumor cell migration. Co-author DOI 10.1016/j.canlet.2015.02.015↗
  7. Comparative proteomic analysis of two stress-management strategies in pancreatic cancer. Co-author PMID 25770192↗
  8. Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action. Co-author PMID 25862846↗
  9. Recurrence 11 years after complete response to gemcitabine, 5-Fluorouracil, and Cisplatin chemotherapy followed by radiotherapy in a patient with advanced panc… Last author PMID 25964569↗
  10. Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0109076↗
  11. Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Co-author PMID 24403454↗
  12. Active hexose-correlated compound down-regulates sex-determining region Y-box 2 of pancreatic cancer cells. Co-author PMID 25202061↗
  13. Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells. Co-author PMID 23898070↗
  14. Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells. Co-author PMID 24222118↗
  15. KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine. Co-author DOI 10.1159/000321019↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kazuyuki Nakamura · 10 shared papers, 2011–2017 · strength 0.46
  2. Yasuhiro Kuramitsu · 10 shared papers, 2011–2017 · strength 0.46
  3. Byron Baron · 7 shared papers, 2013–2017 · strength 0.35
  4. Yufeng Wang · 7 shared papers, 2013–2017 · strength 0.33
  5. Tomoharu Yoshizumi · 4 shared papers, 2015–2019 · strength 0.25
  6. Shinji Itoh · 4 shared papers, 2015–2019 · strength 0.25
  7. Toru Ikegami · 3 shared papers, 2016–2019 · strength 0.21
  8. Yoshinao Oda · 2 shared papers, 2017–2019 · strength 0.16
  9. Daisuke Imai · 2 shared papers, 2017–2019 · strength 0.16
  10. Norifumi Harimoto · 3 shared papers, 2015–2017 · strength 0.16
  11. Shigeyuki Suenaga · 4 shared papers, 2013–2014 · strength 0.15
  12. Isao Sakaida · 4 shared papers, 2011–2014 · strength 0.14
  13. Yuji Soejima · 2 shared papers, 2016–2017 · strength 0.11
  14. Yo Ichi Yamashita · 2 shared papers, 2015–2016 · strength 0.09
  15. Kota Arima · 1 shared paper, 2019 · strength 0.08
  16. Akira Chikamoto · 1 shared paper, 2019 · strength 0.08
  17. Hideo Baba · 1 shared paper, 2019 · strength 0.08
  18. Masahiko Hirota · 1 shared paper, 2019 · strength 0.08
  19. Daisuke Hashimoto · 1 shared paper, 2019 · strength 0.08
  20. Masafumi Inomata · 1 shared paper, 2019 · strength 0.08
  21. Shigeki Nakagawa · 1 shared paper, 2019 · strength 0.08
  22. Masaaki Oka · 1 shared paper, 2015 · strength 0.05
  23. Hideo Baba · 1 shared paper, 2015 · strength 0.05
  24. Tomoyuki Uchihara · 1 shared paper, 2015 · strength 0.05
  25. Ken Shirabe · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.